Covid-19 | Page 14 of 100 | Links Medicus Content Curation & Alerts in Medicine

The total number of deaths associated with #COVID19 worldwide from 2020-2021 may be closer to 14.9 million: New estimates by WHO & @UNDESA.

That’s 9.5 million more deaths than reported https://t.co/qDvaA6t5KZ #HealthData pic.twitter.com/ZjABJzlgiZ

— World Health Organization (WHO) (@WHO) May 5, 2022

Studies show promise for 2 new COVID vaccine platforms.

9 May, 2022 | 02:12h | UTC

Commentary: Studies show promise for 2 new COVID vaccine platforms – CIDRAP

Study 1: Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine – New England Journal of Medicine

Study 2: Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults – New England Journal of Medicine

Editorial: Does the World Still Need New Covid-19 Vaccines?

Commentaries on Twitter

Efficacy of a plant-based vaccine with adjuvant was 69.5% against symptomatic #COVID19 and 78.8% against moderate-to-severe disease. https://t.co/WH54QWCBdg pic.twitter.com/BiEYpJUD7D

— NEJM (@NEJM) May 4, 2022

ZF2001 vaccine has 87% efficacy against critical or severe #COVID19 for at least 6 months after full vaccination and was safe in large cohort of adults. #IDTwitter https://t.co/wsG0AXqI4Y pic.twitter.com/45fqwVrz9a

— NEJM (@NEJM) May 4, 2022

Systematic Review: Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings.

9 May, 2022 | 02:09h | UTC

Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings – Cochrane Library

Summary: Interventions to reduce the risk of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) infection among workers outside healthcare settings – Cochrane Library

Review: SARS-CoV-2 pathogenesis.

6 May, 2022 | 11:01h | UTC

SARS-CoV-2 pathogenesis – Nature Reviews Microbiology

Commentary on Twitter

A Review published in @NatureRevMicro explores recent clinical and experimental advances in understanding SARS-CoV-2 pathogenesis, interactions with host cells and the involvement of the immune system in the development of severe disease. https://t.co/GTm0BZ3ikH pic.twitter.com/jPXFU05Pwm

— Nature Portfolio (@NaturePortfolio) April 23, 2022

Long COVID: aiming for a consensus.

6 May, 2022 | 11:03h | UTC

Long COVID: aiming for a consensus – The Lancet Respiratory Medicine

Commentary on Twitter

There is an urgent need for unification of terminology for the sequelae of #SARSCoV2 infection to ensure that research is directed towards and translated into interventional trials to improve outcomes

NEW Comment—#LongCOVID: aiming for a consensushttps://t.co/dZO4rBVCSY pic.twitter.com/H5ezqL0RLb

— The Lancet Respiratory Medicine (@LancetRespirMed) May 5, 2022

Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study.

5 May, 2022 | 11:02h | UTC

Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study – The BMJ

Commentary on Twitter

In this international, registry based cohort study of patients with covid-19 associated acute respiratory failure, extracorporeal membrane oxygenation was associated with a reduction in mortality by 7.1% compared with conventional mechanical ventilation https://t.co/VkNFeRDQ3j

— The BMJ (@bmj_latest) May 4, 2022

M-A: Efficacy and effectiveness of SARS-CoV-2 vaccines.

5 May, 2022 | 10:26h | UTC

Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis – Vaccines

Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic.

4 May, 2022 | 10:57h | UTC

Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic – STAT

Remdesivir and three other drugs for hospitalized patients with COVID-19: final results of the WHO Solidarity randomized trial and updated meta-analyses.

3 May, 2022 | 11:18h | UTC

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses – The Lancet

Invited Commentary: When and which patients should receive remdesivir? – The Lancet

RCT: Effects of an online breathing and wellbeing program for people with persistent symptoms following COVID-19.

3 May, 2022 | 11:16h | UTC

An online breathing and wellbeing programme (ENO Breathe) for people with persistent symptoms following COVID-19: a parallel-group, single-blind, randomised controlled trial – The Lancet Respiratory Medicine

Invited Commentary: Treating COVID-19-related breathlessness with novel interventions – The Lancet Respiratory Medicine

News Release: Singing techniques can improve quality of life and breathlessness after COVID-19 – Imperial College London

Commentary on Twitter

https://twitter.com/LancetRespirMed/status/1519572126772064256

Systematic Review: Telerehabilitation improves physical function and reduces dyspnea in people with COVID-19 and post-COVID-19 conditions.

3 May, 2022 | 11:05h | UTC

Telerehabilitation improves physical function and reduces dyspnoea in people with COVID-19 and post-COVID-19 conditions: a systematic review – Journal of Physiotherapy

Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?

3 May, 2022 | 11:04h | UTC

POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes – CHEST

COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No – CHEST

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Pfizer says COVID treatment Paxlovid fails to prevent infection of household members.

2 May, 2022 | 00:43h | UTC

Pfizer says COVID treatment Paxlovid fails to prevent infection of household members – Reuters

Commentary on Twitter

Pfizer Inc on Friday said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone who had been exposed to the virus. https://t.co/95zphEYaxc

— Reuters Health (@Reuters_Health) April 29, 2022

RCT: BCG vaccine is not effective in reducing healthcare worker absenteeism in COVID-19 pandemic.

29 Apr, 2022 | 11:05h | UTC

BCG vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial – Clinical Microbiology and Infection

Commentary on Twitter

BCG-CORONA RCT💥 @CMIJournal @MarcBonten
BCG-vaccination of health care worker exposed to #COVID19 patients did NOT reduce unplanned absenteeism nor documented COVID-19 #IDTwitter #MedEd #TwitteRx #MedTwitter https://t.co/yqnpmuy5Y8

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) April 28, 2022

M-A: Household secondary attack rates of SARS-CoV-2 by variant and vaccination status.

29 Apr, 2022 | 10:57h | UTC

Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis – JAMA Network Open

Commentary on Twitter

This systematic review & meta-analysis found household #SARSCoV2 secondary attack rates increased over time and were higher for variants than prior reported estimates. Vaccination was associated with reduced transmission (more for Alpha vs Delta & Omicron) https://t.co/6vwW0u3vY7

— JAMA Network Open (@JAMANetworkOpen) April 28, 2022

Covid-19: What is the evidence for the antiviral Paxlovid?

28 Apr, 2022 | 10:58h | UTC

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis.

28 Apr, 2022 | 10:56h | UTC

Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis – The BMJ

Commentary on Twitter

https://twitter.com/bmj_latest/status/1519430941759918080

Experts fear U.S. may default to annual Covid boosters without sufficient data.

28 Apr, 2022 | 10:51h | UTC

Experts fear U.S. may default to annual Covid boosters without sufficient data – STAT

Commentary on Twitter

Vaccine experts are concerned the U.S. may be sleepwalking into a policy of recommending annual Covid-19 vaccine boosters — without having generated the evidence to show they are actually needed. https://t.co/3TiNZvP0HY

— STAT (@statnews) April 26, 2022

Public health impact of covid-19 vaccines in the US: observational study.

28 Apr, 2022 | 10:54h | UTC

Public health impact of covid-19 vaccines in the US: observational study – The BMJ

Editorial: The benefits of large scale covid-19 vaccination – The BMJ

Commentary on Twitter (thread – click for more)

Paper and accompanying editorial https://t.co/uwqY0PqYsE
"Many more lives could have been saved……
this new study is another confidence booster for covid-19 vaccines." pic.twitter.com/o4FygrAX8T

— Eric Topol (@EricTopol) April 27, 2022

Clinical Review: Diagnosis and management of covid-19 in pregnancy.

27 Apr, 2022 | 08:13h | UTC

Diagnosis and management of covid-19 in pregnancy – The BMJ

Cohort Study: Incidence of Guillain-Barré syndrome after Covid-19 vaccination in the vaccine safety datalink.

27 Apr, 2022 | 08:03h | UTC

Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink – JAMA Network Open

Commentary on Twitter

This cohort study of #COVID19 vaccine safety surveillance in the US Vaccine Safety Datalink found a small elevated risk of Guillain-Barré syndrome after Janssen/J&J vaccine but not after mRNA COVID-19 vaccines. @KPDOR https://t.co/TTya5BDqeV

— JAMA Network Open (@JAMANetworkOpen) April 26, 2022

Covid-19: Only a quarter of patients admitted to hospital feel fully recovered after a year, study finds.

26 Apr, 2022 | 08:45h | UTC

Covid-19: Only a quarter of patients admitted to hospital feel fully recovered after a year, study finds – The BMJ

Original Study: Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study – The Lancet Respiratory Medicine

Invited Commentary: Long COVID: systemic inflammation and obesity as therapeutic targets – The Lancet Respiratory Medicine

Commentary on Twitter (thread – click for more)

PHOSP-COVID study:
– 232 (29%) of 804 pts fully recovered at 1y
– Female sex, obesity, & IMV = less likely to feel fully recovered
– inflamm mediators📈in those w/ most severe physical, mental health, & cognitive impairments

Read it here: https://t.co/rVZuVDo4xl

— The Lancet Respiratory Medicine (@LancetRespirMed) April 25, 2022

Persistent COVID-19 symptoms in a community study of 606,434 people in England.

26 Apr, 2022 | 08:48h | UTC

Persistent COVID-19 symptoms in a community study of 606,434 people in England – Nature Communications

Commentary on Twitter

Thirty-eight percent of participants from a community-based study of symptoms following COVID-19 reported persistent symptoms that lasted 12 weeks or more, according to an article published in @NatureComms. https://t.co/sAEutdOkSS pic.twitter.com/oCyyXGIRbk

— Nature Portfolio (@NaturePortfolio) April 20, 2022